Possible New Alzheimer's Drug: Annovis Bio (ANVS)

Schwab Network

English - June 11, 2021 18:37 - 6 minutes - 35.8 MB - ★★★★★ - 23 ratings
News Commentary News Business News business news news commentary news Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Splash Beverage (SBEV) Company Overview

Next Episode: Investing In A.I. & Stocks To Watch: NICE, NUAN, BPRMF, ZEN

Annovis Bio (ANVS) is developing a drug that improves cognition and motor function among patients with Alzheimer’s and Parkinson’s Diseases. Founder and CEO, Maria Maccecchini, discusses what separates the Annovis Bio treatment from other therapies. Annovis Bio’s stock hit an all-time high on May 25th and Maccecchini has a very positive outlook for the future of the drug and company. Tune in to find out more.